Ellipses Pharma Limited today announced that the Company is exploring a listing opportunity on the main market of the London ...
The oncology biotech could go public in a SPAC reverse takeover, though an IPO is not guaranteed.
Ellipses Pharma, the London-based oncology drug development company, said it is exploring a listing on the main market of the London Stock Exchange through a reverse takeover of Wolfram Resources, a ...
(LSE:WFR) in a reverse merger transaction on November 18, 2026. Consideration for the Proposed Acquisition is expected to be ...
A cancer drug venture backed by a group of celebrity investors and Middle Eastern wealth is planning to list on the London ...
Nov 18 (Reuters) - British cancer drug developer Ellipses Pharma on Wednesday said it was exploring a London listing through ...